20 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
iABC Programme (IABC PROGRAMME)
Date du début: 1 août 2015, Date de fin: 31 juil. 2020,
Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10,000) people in the EU. Chronic bacterial pulmonary infection leading to an irreversible decline in lung structure and function is the main cause of mortality and morbidity in patients with CF, with more than 95% of deaths due to respiratory failure. Pseudomon ...
Voir le projet
21
Participants partenaires
TERMINÉ
European Prevention of Alzheimer’s Dementia Consortium (EPAD)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,
Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infras ...
Voir le projet
40
Participants partenaires
TERMINÉ
Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies (SPRINTT)
Date du début: 1 juil. 2014, Date de fin: 30 juin 2019,
The current healthcare systems are built around the traditional paradigm of patients suffering from a single acute illness. They are therefore largely unprepared to face the increasing demands for health services arising from the expansion of an older population with specific medical needs related to multiple chronic disorders. As a consequence, the medical conditions of a large and growing seg ...
Voir le projet
27
Participants partenaires
TERMINÉ
Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.Approach: To achieve this vision through a public-private partnership, ADVANCE partners 1. establish common grounds and rules for collaboration between public and ...
Voir le projet
30
Participants partenaires
TERMINÉ
Oral biopharmaceutics tools (ORBITO)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,
The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Voir le projet
28
Participants partenaires
TERMINÉ
Recognising Adverse Drug Reactions (WEB-RADR)
Date du début: 1 sept. 2014, Date de fin: 31 août 2017,
WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Voir le projet
20
Participants partenaires
TERMINÉ
Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)
Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,
The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Voir le projet
39
Participants partenaires
TERMINÉ
European Patients' Academy on Therapeutic Innovation (EUPATI)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,
"The proposed project ""European Patients' Academy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocat ...
Voir le projet
33
Participants partenaires
TERMINÉ
Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities (ETOX)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2016,
The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Voir le projet
30
Participants partenaires
TERMINÉ
Incorporating real-life clinical data into drug development (GETREAL)
Date du début: 1 oct. 2013, Date de fin: 31 déc. 2016,
When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and efficacy of the medicine in a clinical trial setting. However, assessing the expected future value of the medicines when used in “real world” clinical practice requires additional information next to traditional (pre-authorisation) clinical trials. Regulatory, HTA ...
Voir le projet
32
Participants partenaires
TERMINÉ
European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)
Date du début: 1 janv. 2010, Date de fin: 30 nov. 2016,
Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Voir le projet
34
Participants partenaires
TERMINÉ
European Medicines Research Training Network (EMTRAIN)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2016,
EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will establish a pan-European platform of excellence for education and training covering the whole life-cycle of medicines from basic research through clinical development to pharmaco-vigilance. It will underpin the successful delivery of the current and future IMI-f ...
Voir le projet
32
Participants partenaires
TERMINÉ
European programme in Pharmacovigilance and Pharmacoepidemiology (EU2P)
Date du début: 1 sept. 2009, Date de fin: 30 juin 2016,
The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia at the European level. It will give access to a harmonised training programme that gathers complementary specialized and eminent European partners. The Eu2P consortium consists of course providers with aproven record including the University of Bordeaux (Eu2P ...
Voir le projet
24
Participants partenaires
TERMINÉ
Electronic Health Record systems for Clinical Research (EHR4CR)
Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,
Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost pressures on healthcare systems and the pharmaceutical industry. Clinical research is also growing in complexity, labour intensity and cost. There is a growing realization that the development and integration of Electronic Health Record systems (EHRs) for medical ...
Voir le projet
37
Participants partenaires
TERMINÉ
The Open Pharmacological Concepts Triple Store (OPEN PHACTS)
Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,
Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data alongside internal. Analysis and hypothesis generation for drug-discovery projects requires assembly, overlay and comparison of data from many sources, requiring shared identifiers and common semantics. Expression profiles need to be overlaid with gene or pathway identifiers an ...
Voir le projet
32
Participants partenaires
TERMINÉ
Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2015,
RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this bottleneck results from: a lack of useful and validated biomarkers, underperforming pre-clinical models, inadequate and incomplete sub-phenotyping, and insufficient disease understanding.HypothesisThe use of biomarker profiles comprised of various types of hi ...
Voir le projet
42
Participants partenaires
TERMINÉ
Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes (IMIDIA)
Date du début: 1 févr. 2010, Date de fin: 30 sept. 2015,
An absolute or relative loss of beta-cell mass and function underlie the development of type I and type 2 diabetes.Preventing beta-cell demise or restoring their number and function is a major therapeutic goal. However,development of novel diagnostic and prognostic tools, and of novel therapeutic modalities, is hampered by the limited knowledge of the molecular pathways that control beta-cell demi ...
Voir le projet
23
Participants partenaires
TERMINÉ
SAFER AND FASTER EVIDENCE-BASED TRANSLATION (SAFE-T)
Date du début: 15 juin 2009, Date de fin: 14 juin 2015,
The public-private consortium composed of complementary SMEs, academic and clinical centers of excellence and EMEA as partner proposes SAFE-T (Safer And Easter Evidence-based Iranslation) project for the establishment of a biomarker (BM) qualification process and its validation in clinical biomarker studies designed for the translation, performance testing and eventual regulatory qualifIcatIon of ...
Voir le projet
26
Participants partenaires
TERMINÉ
Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS)
Date du début: 1 sept. 2009, Date de fin: 28 févr. 2015,
Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical ...
Voir le projet
20
Participants partenaires
TERMINÉ
Pharmaceutical Medicine Training Programme (PHARMATRAIN)
Date du début: 1 mai 2009, Date de fin: 30 avr. 2014,
"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Voir le projet